AvenCell Europe GmbH

Our Story

After 10 years of private ownership, GEMoaB joined forces with the US-based and leading clinical-stage genome editing company Intellia Therapeutics to develop “off-the-shelf” universal CAR-T cell therapies for immuno-oncology and autoimmune diseases. Financed by the private investment platform Blackstone Life Sciences, the novel CAR-T cell company AvenCell Therapeutics was launched to combine GEMoaB’s world-leading clinical-stage universal CAR-T platforms with Intellia’s allogeneic cell platform and CRISPR cell engineering. 

GEMoaB became a daughter company of AvenCell Therapeutics based in Cambridge, Massachusetts and changed its name into AvenCell Europe.